PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $0.07 by 2419.44 percent. This is a 96.47 percent decrease over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $164.677 million which missed the analyst consensus estimate of $276.665 million by 40.48 percent. This is a 22.75 percent decrease over sales of $213.172 million the same period last year.